Skip to main content

Table 1 Medications in use before the enrollment for the 16-week period of run-in

From: Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial

  Dapagliflozin Glibenclamide p
Metformin, % 96 98 1.0
Sulfonylureas, % 41 49 0.5
DPP-4i, % 4 14 0.16
Pioglitazone, % 2 0 1.0
ACEi, % 6 2 0.6
ARB, % 50 50 1.0
Statins, % 45 43 1.0
  1. DPP-4i dipeptidyl peptidase-4 inhibitors, ACEi angiotensin-converting-enzyme inhibitor, ARB angiotensin-receptor blockers